Biodexa Pharmaceuticals PLC 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Biodexa Pharmaceuticals PLC reported recurring losses and significant cash outflows, raising substantial doubt about its ability to continue as a going concern, despite advancing its clinical pipeline with new licensing agreements and grant funding.
NASDAQ
Biodexa Pharmaceuticals PLC reports its financial results for the year ended December 31, 2024, highlighting ongoing development efforts and strategic financial activities.
NASDAQ
Biodexa Pharmaceuticals PLC files its 20-F, detailing financial results for the year ended December 31, 2023, and outlining its strategic focus on clinical development and licensing.